Darolutamide plus androgen-deprivation therapy and docetaxel for mHSPC in subgroups of the ARASENS trial

The phase 3 ARASENS trial showed that addition of darolutamide to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer was associated with improved overall survival (OS). Subgroup analyses of the trial found that darolutamide improved OS in high-volume and in high- and low-risk patients with HRs consistent across all subgroups and similar to the overall population. Darolutamide did not increase the toxicity associated with ADT and docetaxel in disease volume and risk subgroups.